<DOC>
	<DOCNO>NCT02172794</DOCNO>
	<brief_summary>The primary objective study evaluate effect tiotropium gross muscular efficiency</brief_summary>
	<brief_title>Tiotropium Inhalation Capsules Salmeterol Inhalation Aerosol Muscular Efficiency Resting Energy Expenditure ( REE ) Patients With Stable Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . All patient sign inform consent consistent ICHGCP guideline prior participation trial , include medication washout restriction . 2 . Male female patient 40 year age old . 3 . All patient diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients moderate severe airway obstruction postbronchodilator FEV1/FVC ≤ 70 % FEV1 ≤ 60 % predict ( Visit 1 ) . 4 . FEV1 % predict and/or force vital capacity ( FVC ) increase &gt; 5 % inhalation 480 μg salbutamol 80 μg ipratropium 5 . Patients current exsmokers smoke history 10 packyears . 6 . Patients able perform technically acceptable pulmonary function test able maintain record ( Patient Daily Record ) study period require protocol . 7 . Patients able inhale medication HandiHaler , inhalation aerosol . 8 . Patients ventilatory limitation maximal exercise capacity : Increase arterial carvon dioxide tension ( PaCO2 ) incremental bicycle test and/or increase minute ventilation ( VE ) max &gt; 80 % ( FEV1 x 37.5 ) 9 . Patients Wmax ≥ 40 Watt maximal incremental bicycle test . 1 . Increase blood lactate &gt; 10 mmol/L peak exercise 2 . Increase blood lactate &gt; 2.5 mmol/L ≥ 50 % Wmax 3 . Decrease oxygen saturation 90 % ≥ 50 % Wmax 4 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 5 . Patients clinically relevant abnormal haemoglobulin , leukocytes , thrombocyte , glucose , sodium , potassium . 6 . Patients recent history ( i.e. , six month less ) myocardial infarction . 7 . Patients cardiac arrhythmia require drug therapy hospitalise heart failure within past three year . 8 . Patients know active tuberculosis . 9 . Patients oxygen therapy . 10 . Patients history cystic fibrosis , bronchiectasis , interstitial lung disease , pulmonary thromboembolic disease . 11 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion 4 . 12 . Patients respiratory infection six week prior Screening Visit ( Visit 1 ) baseline period . The enrolment patient postpone least six week . 13 . Patients frequent exacerbation ( least three precede year ) could expect interfere patient 's ability participate trial exclude . 14 . Patients know hypersensitivity anticholinergic drug , beta adrenergic , lactose component inhalation capsule delivery system . 15 . Patients history cancer within last three year . Patients treat basal cell carcinoma allow . Patients successfully treat cancer great five year prior entry allow . 16 . Patients know symptomatic prostatic hypertrophy bladder neck obstruction . 17 . Patients know narrowangle glaucoma . 18 . Patients treat cromolyn sodium nedocromil sodium . 19 . Patients treated antihistamine ( H1 receptor antagonist ) . 20 . Patients treat theophylline 21 . Patients currently βblocker therapy . 22 . Patients use oral corticosteroid medication unstable dos ( i.e . le six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 23 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous 3 month ( i.e . oral contraceptive , intrauterine device , diaphragm subdermal implant e.g . Norplant ) . 24 . Patients history asthma allergic rhinitis total blood eosinophil count ≥600 /mm3 . A repeat eosinophil count conduct patient ( Criterion modify Protocol Amendment 2 ) . 25 . Patients significant alcohol drug abuse within past two year . 26 . Patients take investigational drug within one month six half life ( whichever great ) prior Screening Visit ( Visit 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>